Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis
- 19 November 2021
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 97 (2) , 203-208
Abstract
Adult Langerhans cell histiocytosis (LCH) remains poorly defined. We retrospectively studied 266 newly diagnosed LCH patients to understand the clinical presentation, treatment, and prognosis of adult LCH. The median age at diagnosis was 32 years (range, 18–79 years). At the time of diagnosis, 40 patients had single lesions within a single system, 18 patients had single pulmonary LCH, 26 patients had multiple lesions within a single system (SS‐m), and 182 patients had multisystem disease (MS). The most common organ involved in MS patients was the bone (69.8%), followed by the pituitary (61.5%) and lung (61.0%). BRAFV600E, BRAF deletion, and MAP2K1 mutation were detected in 38.8%, 25.4%, and 19.4% patients, respectively. BRAF deletion was found more common in patients with MS LCH compared to single‐system LCH (38.5% vs 7.1%, p = .004), also in patients with liver involvement (69.2% vs 14.3%, p < .001). The estimated 3‐year overall survival (OS) and event‐free survival (EFS) rates were 94.4% and 54.7%, respectively, in SS‐m and MS LCH. Multivariate Cox regression showed that involvement of the liver or spleen at baseline predicted poor EFS and receiving cytarabine‐based therapy as a first‐line treatment and age older than 30 years at diagnosis predicted favorable EFS. The involvement of risk organs and age older than 50 years predicted poor OS, and receiving cytarabine‐based therapy predicted favorable OS. Therefore, BRAF deletion was correlated with MS LCH, particularly those with liver involvement. Liver or spleen involvement at baseline indicates a poor prognosis, and a cytarabine‐based regimen could be considered as first‐line treatment for adult LCH patients.Keywords
Funding Information
- Chinese Academy of Medical Sciences (2019‐RC‐HL‐001)
- Natural Science Foundation of Beijing Municipality (7202160)
This publication has 19 references indexed in Scilit:
- Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineagesBlood, 2016
- Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2Cancer Cell, 2016
- Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective studyLeukemia Research, 2016
- Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120Cancer Discovery, 2016
- MAP2K1 and MAP3K1 mutations in langerhans cell histiocytosisGenes, Chromosomes and Cancer, 2015
- Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutationBlood, 2014
- Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosisBlood, 2013
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Langerhans cell histiocytosis in adultsReport from the International Registry of the Histiocyte SocietyEuropean Journal of Cancer, 2003
- Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with langerhans cell histiocytosisMedical and Pediatric Oncology, 1989